(Q41126166)

27 September 2017

Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients (English)

1 reference

27 September 2017

11

Frederik Barkhof

1 reference

27 September 2017

12

Joep Killestein

1 reference

27 September 2017

Mike P Wattjes

1

1 reference

27 September 2017

Martijn T Wijburg

2

1 reference

27 September 2017

Anke Vennegoor

3

1 reference

27 September 2017

Birgit I Witte

4

1 reference

27 September 2017

Stefan D Roosendaal

5

1 reference

27 September 2017

Esther Sanchez

6

1 reference

27 September 2017

Yaou Liu

7

1 reference

27 September 2017

Carine O Martins Jarnalo

8

1 reference

27 September 2017

Nancy D Richert

9

1 reference

27 September 2017

Bernard Mj Uitdehaag

10

1 reference

27 September 2017

12 November 2015

1 reference

Multiple Sclerosis Journal

27 September 2017

1 reference

27 September 2017

22

1 reference

27 September 2017

9

1 reference

27 September 2017

1174-1183

1 reference

Requirement for safety monitoring for approved multiple sclerosis therapies: an overview

27 September 2017

1 reference

https://api.crossref.org/works/10.1177%2F1352458515615225

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515615225

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515615225

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515615225

Natalizumab: bench to bedside and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515615225

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515615225

Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515615225

MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515615225

Presymptomatic diagnosis with MRI and adequate treatment ameliorate the outcome after natalizumab-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515615225

Asymptomatic progressive multifocal leukoencephalopathy associated with natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515615225

Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515615225

Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515615225

MRI pattern in asymptomatic natalizumab-associated PML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515615225

Outcome and survival of asymptomatic PML in natalizumab-treated MS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515615225

The earlier, the smaller, the better for natalizumab-associated PML: in MRI vigilance veritas?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515615225

Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515615225

The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515615225

Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515615225

PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515615225

Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS manifestation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515615225

The Measurement of Observer Agreement for Categorical Data

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515615225

Measuring nominal scale agreement among many raters

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515615225

MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515615225

Imaging outcomes for neuroprotection and repair in multiple sclerosis trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515615225

Clinical effects of natalizumab on multiple sclerosis appear early in treatment course

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515615225

A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515615225

Interobserver agreement on the radiological criteria of the International Panel on the diagnosis of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515615225

Progressive multifocal leukoencephalopathy: diffusion-weighted imaging and pathological correlations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515615225

Improved detection of active multiple sclerosis lesions: 3D subtraction imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515615225

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515615225

Reduced diffusion in a subset of acute MS lesions: a serial multiparametric MRI study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515615225

21 January 2018

Identifiers

DOI

10.1177/1352458515615225

1 reference

27 September 2017

1 reference